Plasma Asymmetric Dimethylarginine and Nitric Oxide Levels on Early Prognosis in Patients with Myocardial Infarction

被引:1
作者
Turkes, Sukran [1 ]
Erdenen, Fusun [1 ]
Muderrisoglu, Cuneyt [1 ]
Genc, Habibe [2 ]
Uzun, Hafize [2 ]
Aral, Hale [3 ]
Guvenen, Guvenc [3 ]
机构
[1] Istanbul Training & Res Hosp, Dept Internal Med, Istanbul, Turkey
[2] Istanbul Training & Res Hosp, Dept Biochem Lab, Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Fac Med, Dept Biochem, Istanbul, Turkey
来源
ISTANBUL MEDICAL JOURNAL | 2011年 / 12卷 / 04期
关键词
Asymmetric dimethylarginine; endothelial dysfunction; myocardial infarction; nitric oxide; left ventricular dysfunction;
D O I
10.5505/1304.8503.2011.60602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: It is unclear whether abnormalities of nitric oxide (NO) are related to hemodynamic dysfunction and mortality in patients after acute myocardial infarction (MI). We investigated the relationship of plasma asymmetric dimethylarginine (ADMA) and NO levels with early prognosis in patients with MI. Methods: Fifty-nine patients (9 females, 50 males, aged 32-75) hospitalized in the Coronary Care Unit were included in the study. Blood samples were obtained on the first day of admission for routine hematological and biochemical tests and for plasma ADMA and NO levels. NO was determined as the concentration of nitrate plus nitrite (NO metabolites) spectrophotometrically at 430 nm using the Griess reaction. ADMA concentrations were determined by competitive ELISA assay. One month after MI, echocardiography was performed on 56 patients who survived, and left ventricular ejection fraction (LVEF) was investigated as a prognostic marker of cardiac function. Results: There was no correlation between ADMA and NO levels with age, gender, smoking, localization of the infarction, history of hypertension, coronary heart disease or diabetes mellitus, and the levels of total cholesterol, triglyceride, lactate dehydrogenase, white blood cells, and Creactive protein. Plasma ADMA concentrations were negatively correlated with NO levels (r=-0.72) and creatine kinase -MB levels (r=-0.37). LVEF had no correlation with ADMA or NO levels (p>0.05). Conclusion: In previous studies, decreased NO and high levels of ADMA were proposed as independent risk factors for coronary artery disease. Although MI patients had higher ADMA levels, they showed no correlation with left ventricular systolic function or early cardiac events.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 20 条
  • [1] Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment
    Bae, SW
    Stühlinger, MC
    Yoo, HS
    Yu, KH
    Park, HK
    Choi, BY
    Lee, YS
    Pachinger, O
    Choi, YH
    Lee, SH
    Park, JE
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (06) : 729 - 733
  • [2] When the endothelium cannot say 'NO' anymore -: ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease
    Böger, RH
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (21) : 1901 - 1902
  • [3] The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
    Böger, RH
    [J]. CARDIOVASCULAR RESEARCH, 2003, 59 (04) : 824 - 833
  • [4] Cengel Atiye, 2006, Anadolu Kardiyol Derg, V6, P364
  • [5] Role of endothelial dysfunction in atherosclerosis
    Davignon, J
    Ganz, P
    [J]. CIRCULATION, 2004, 109 (23) : 27 - 32
  • [6] Endothelial function and dysfunction - Testing and clinical relevance
    Deanfield, John E.
    Halcox, Julian P.
    Rabelink, Ton J.
    [J]. CIRCULATION, 2007, 115 (10) : 1285 - 1295
  • [7] Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure
    Dueckelmann, Christina
    Mittermayer, Friedrich
    Haider, Dominik Georg
    Altenberger, Johann
    Eichinger, Joerg
    Wolzt, Michael
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (09) : 2037 - 2042
  • [8] Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin
    Eid, HM
    Eritsland, J
    Larsen, J
    Arnesen, H
    Seljeflot, I
    [J]. ATHEROSCLEROSIS, 2003, 166 (02) : 279 - 284
  • [9] NITRIC-OXIDE SYNTHASES IN MAMMALS
    KNOWLES, RG
    MONCADA, S
    [J]. BIOCHEMICAL JOURNAL, 1994, 298 : 249 - 258
  • [10] Nitric oxide therapies in vascular diseases
    Kurowska, EM
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (03) : 155 - 166